201 related articles for article (PubMed ID: 31467357)
1. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
Beetham H; Chen A; Telford BJ; Single A; Jarman KE; Lackovic K; Luxenburger A; Guilford P
Sci Rep; 2019 Aug; 9(1):12511. PubMed ID: 31467357
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
Godwin TD; Kelly ST; Brew TP; Bougen-Zhukov NM; Single AB; Chen A; Stylianou CE; Harris LD; Currie SK; Telford BJ; Beetham HG; Evans GB; Black MA; Guilford PJ
Gastric Cancer; 2019 Mar; 22(2):273-286. PubMed ID: 30066183
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.
Telford BJ; Chen A; Beetham H; Frick J; Brew TP; Gould CM; Single A; Godwin T; Simpson KJ; Guilford P
Mol Cancer Ther; 2015 May; 14(5):1213-23. PubMed ID: 25777964
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Chen I; Mathews-Greiner L; Li D; Abisoye-Ogunniyan A; Ray S; Bian Y; Shukla V; Zhang X; Guha R; Thomas C; Gryder B; Zacharia A; Beane JD; Ravichandran S; Ferrer M; Rudloff U
J Transl Med; 2017 May; 15(1):92. PubMed ID: 28460635
[TBL] [Abstract][Full Text] [Related]
5. Germline E-cadherin mutations in familial lobular breast cancer.
Masciari S; Larsson N; Senz J; Boyd N; Kaurah P; Kandel MJ; Harris LN; Pinheiro HC; Troussard A; Miron P; Tung N; Oliveira C; Collins L; Schnitt S; Garber JE; Huntsman D
J Med Genet; 2007 Nov; 44(11):726-31. PubMed ID: 17660459
[TBL] [Abstract][Full Text] [Related]
6. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study.
Benusiglio PR; Malka D; Rouleau E; De Pauw A; Buecher B; Noguès C; Fourme E; Colas C; Coulet F; Warcoin M; Grandjouan S; Sezeur A; Laurent-Puig P; Molière D; Tlemsani C; Di Maria M; Byrde V; Delaloge S; Blayau M; Caron O
J Med Genet; 2013 Jul; 50(7):486-9. PubMed ID: 23709761
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
[TBL] [Abstract][Full Text] [Related]
8. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.
Luxenburger A; Bougen-Zhukov N; Fraser MG; Beetham H; Harris LD; Schmidt D; Cameron SA; Guilford PJ; Evans GB
J Med Chem; 2021 Dec; 64(24):18114-18142. PubMed ID: 34878770
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic and prophylactic gastrectomy in a family with hereditary diffuse gastric cancer secondary to a CDH1 mutation: a case series.
Gjyshi O; Vashi P; Seewald L; Kohan M; Abboud E; Fowler E; Suppiah R; Halabi H
World J Surg Oncol; 2018 Jul; 16(1):143. PubMed ID: 30007404
[TBL] [Abstract][Full Text] [Related]
10. Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC).
Lo W; Zhu B; Sabesan A; Wu HH; Powers A; Sorber RA; Ravichandran S; Chen I; McDuffie LA; Quadri HS; Beane JD; Calzone K; Miettinen MM; Hewitt SM; Koh C; Heller T; Wacholder S; Rudloff U
J Med Genet; 2019 Jun; 56(6):370-379. PubMed ID: 30745422
[TBL] [Abstract][Full Text] [Related]
11. Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome.
Molinaro V; Pensotti V; Marabelli M; Feroce I; Barile M; Pozzi S; Laghi L; Serrano D; Bernard L; Bonanni B; Ranzani GN
Genes Chromosomes Cancer; 2014 May; 53(5):432-45. PubMed ID: 24493355
[TBL] [Abstract][Full Text] [Related]
12. CDH1 germline mutations in families with hereditary lobular breast cancer.
Girardi A; Magnoni F; Vicini E; Kouloura A; La Vecchia C; Veronesi P; Corso G
Eur J Cancer Prev; 2022 May; 31(3):274-278. PubMed ID: 33990097
[TBL] [Abstract][Full Text] [Related]
13. Hereditary diffuse gastric cancer: association with lobular breast cancer.
Schrader KA; Masciari S; Boyd N; Wiyrick S; Kaurah P; Senz J; Burke W; Lynch HT; Garber JE; Huntsman DG
Fam Cancer; 2008; 7(1):73-82. PubMed ID: 18046629
[TBL] [Abstract][Full Text] [Related]
14. Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature.
Obermair F; Rammer M; Burghofer J; Malli T; Schossig A; Wimmer K; Kranewitter W; Mayrbaeurl B; Duba HC; Webersinke G
Fam Cancer; 2019 Apr; 18(2):253-260. PubMed ID: 30306390
[TBL] [Abstract][Full Text] [Related]
15. Clinical spectrum and pleiotropic nature of
Figueiredo J; Melo S; Carneiro P; Moreira AM; Fernandes MS; Ribeiro AS; Guilford P; Paredes J; Seruca R
J Med Genet; 2019 Apr; 56(4):199-208. PubMed ID: 30661051
[No Abstract] [Full Text] [Related]
16. Cancer predisposition and germline CTNNA1 variants.
Lobo S; Benusiglio PR; Coulet F; Boussemart L; Golmard L; Spier I; Hüneburg R; Aretz S; Colas C; Oliveira C
Eur J Med Genet; 2021 Oct; 64(10):104316. PubMed ID: 34425242
[TBL] [Abstract][Full Text] [Related]
17. CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
Adib E; El Zarif T; Nassar AH; Akl EW; Abou Alaiwi S; Mouhieddine TH; Esplin ED; Hatchell K; Nielsen SM; Rana HQ; Choueiri TK; Kwiatkowski DJ; Sonpavde G
Br J Cancer; 2022 Mar; 126(5):797-803. PubMed ID: 34949788
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management.
Suriano G; Yew S; Ferreira P; Senz J; Kaurah P; Ford JM; Longacre TA; Norton JA; Chun N; Young S; Oliveira MJ; Macgillivray B; Rao A; Sears D; Jackson CE; Boyd J; Yee C; Deters C; Pai GS; Hammond LS; McGivern BJ; Medgyesy D; Sartz D; Arun B; Oelschlager BK; Upton MP; Neufeld-Kaiser W; Silva OE; Donenberg TR; Kooby DA; Sharma S; Jonsson BA; Gronberg H; Gallinger S; Seruca R; Lynch H; Huntsman DG
Clin Cancer Res; 2005 Aug; 11(15):5401-9. PubMed ID: 16061854
[TBL] [Abstract][Full Text] [Related]
19. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Cho SY; Park JW; Liu Y; Park YS; Kim JH; Yang H; Um H; Ko WR; Lee BI; Kwon SY; Ryu SW; Kwon CH; Park DY; Lee JH; Lee SI; Song KS; Hur H; Han SU; Chang H; Kim SJ; Kim BS; Yook JH; Yoo MW; Kim BS; Lee IS; Kook MC; Thiessen N; He A; Stewart C; Dunford A; Kim J; Shih J; Saksena G; Cherniack AD; Schumacher S; Weiner AT; Rosenberg M; Getz G; Yang EG; Ryu MH; Bass AJ; Kim HK
Gastroenterology; 2017 Aug; 153(2):536-549.e26. PubMed ID: 28522256
[TBL] [Abstract][Full Text] [Related]
20. Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk.
Gamble LA; Rossi A; Fasaye GA; Kesserwan C; Hernandez JM; Blakely AM; Davis JL
JAMA Surg; 2022 Jan; 157(1):18-22. PubMed ID: 34643667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
